Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Genzyme/IG Labs

This article was originally published in The Gray Sheet

  • News

Executive Summary

Genzyme/IG Labs: Enter agreement in principle under which Genzyme would acquire all publicly held shares of genetic testing services company IG Labs in a tax-free merger worth approximately $21 mil. According to terms of the proposed deal, public stockholders of IG Labs would receive $7 in Genzyme General Division common stock for each IG Labs share. Genzyme's General Division consists of therapeutics, diagnostic products and services, pharmaceuticals and fine chemicals...

Table

View full table

Tags:
Latest Headlines

Front Line Medical Technologies Announce CE Mark For COBRA-OS

Recalls Round-Up: Class 1s For BioMérieux, Fresenius, Draeger, More

New Guidance For Breast Cancer Screening Drops Age Of First Scan To 40

CDRH’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

See All
UsernamePublicRestriction

Register

MT004120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By